Johnson & Johnson (JNJ) on Tuesday announced positive results from the Phase 3 FUZION study evaluating TREMFYA in adults with active perianal fistulizing Crohn's disease.
The study met its primary endpoint of combined fistula remission at Week 24, defined as complete closure of all external fistula openings with no drainage, no new fistulas, and no evidence of underlying fluid collections on MRI.
The treatment showed statistically significant improvements compared with placebo, and adverse events through 24 weeks were consistent with the known safety profile of TREMFYA in Crohn's disease.
JNJ shares closed at $224.20 on Monday, down 1.32%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.